M. Laguna (2014)
Re: Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial DataThe Journal of Urology, 192
M. Hölzel, T. Tüting (2016)
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis.Trends in immunology, 37 6
E. Saâda-Bouzid, C. Defaucheux, A. Karabajakian, Virginia Coloma, V. Servois, X. Paoletti, C. Even, J. Fayette, J. Guigay, D. Loirat, E. Romano, C. Tourneau (2016)
Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD1/PD-L1 inhibitors.Journal of Clinical Oncology, 34
F. Colotta, P. Allavena, A. Sica, C. Garlanda, A. Mantovani (2009)
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.Carcinogenesis, 30 7
C. Gomez-Roca, S. Koscielny, V. Ribrag, C. Dromain, I. Marzouk, F. Bidault, R. Bahleda, C. Ferté, C. Massard, J. Soria (2011)
Tumour growth rates and RECIST criteria in early drug development.European journal of cancer, 47 17
J. Goronzy, C. Weyand (2013)
Understanding immunosenescence to improve responses to vaccinesNature Immunology, 14
J. Wolchok, A. Hoos, S. O'Day, J. Weber, O. Hamid, C. Lebbé, M. Maio, Michael Binder, O. Bohnsack, G. Nichol, R. Humphrey, Stephen Hodi (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 15
R. Motzer, B. Escudier, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, T. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. Gauler, Takeshi Ueda, Yoshihiko Tomita, F. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. Simon, Li-an Xu, I. Waxman, P. Sharma (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.The New England journal of medicine, 373 19
Neutrophils (1e+9/l)
Bao-Jun Yang, Xinxin Han, L. Yin, M. Xing, Zhi-hong Xu, Hong-Wei Xue (2016)
Arabidopsis PROTEASOME REGULATOR1 is required for auxin-mediated suppression of proteasome activity and regulates auxin signallingNature Communications, 7
M. Nishino, S. Dahlberg, L. Fulton, S. Digumarthy, H. Hatabu, B. Johnson, L. Sequist (2016)
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.Academic radiology, 23 3
W. Mellema, S. Burgers, E. Smit (2015)
Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report.Lung cancer, 87 2
Neĭman Im (1974)
[Inflammation and cancer].Patologicheskaia fiziologiia i eksperimental'naia terapiia, 0 4
(2016)
American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
F. Hodi, W. Hwu, R. Kefford, J. Weber, A. Daud, O. Hamid, A. Patnaik, A. Ribas, C. Robert, T. Gangadhar, A. Joshua, P. Hersey, R. Dronca, R. Joseph, D. Hille, Dahai Xue, Xiaoyun Li, S. Kang, S. Ebbinghaus, A. Perrone, J. Wolchok (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 13
S. Ansell, A. Lesokhin, I. Borrello, A. Halwani, E. Scott, M. Gutierrez, S. Schuster, M. Millenson, D. Cattry, G. Freeman, S. Rodig, B. Chapuy, A. Ligon, Lili Zhu, J. Grosso, S. Kim, J. Timmerman, M. Shipp, P. Armand (2015)
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.The New England journal of medicine, 372 4
J. Lahmar, F. Facchinetti, S. Koscielny, C. Ferté, L. Mezquita, M. Bluthgen, C. Lindsay, J. Adam, D. Planchard, J. Soria, B. Besse, C. Caramella (2016)
Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 34
C. Robert, J. Schachter, G. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, O. Hamid, C. Mateus, R. Shapira-Frommer, M. Kosh, Honghong Zhou, N. Ibrahim, S. Ebbinghaus, A. Ribas (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.The New England journal of medicine, 372 26
Gregory Riely, M. Kris, Binsheng Zhao, T. Akhurst, D. Milton, E. Moore, L. Tyson, W. Pao, N. Rizvi, L. Schwartz, V. Miller (2007)
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of EverolimusClinical Cancer Research, 13
C. Ferté, Marianna Fernandez, A. Hollebecque, S. Koscielny, A. Lévy, C. Massard, R. Balheda, B. Bot, C. Gomez-Roca, C. Dromain, S. Ammari, J. Soria (2013)
Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical TrialsClinical Cancer Research, 20
R. Iacovelli, F. Massari, L. Albiges, Y. Loriot, C. Massard, K. Fizazi, B. Escudier (2015)
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.European urology, 68 1
Ö. Strannegård, F. Thorén (2015)
Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha – can tumor immune escape after immunotherapy accelerate disease progression?Oncoimmunology, 5
J. Rosenberg, J. Hoffman-Censits, T. Powles, M. Heijden, A. Balar, A. Necchi, N. Dawson, P. O’Donnell, A. Balmanoukian, Y. Loriot, S. Srinivas, M. Retz, P. Grivas, R. Joseph, M. Galsky, M. Fleming, D. Petrylak, J. Pérez-Gracia, H. Burris, D. Castellano, C. Canil, J. Bellmunt, D. Bajorin, D. Nickles, R. Bourgon, G. Frampton, N. Cui, S. Mariathasan, O. Abidoye, G. Fine, R. Dreicer (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 387
Eggermont is a consultant/advisory board member for Actelion, Bristol-Myers Squibb, Incyte, MSD, and Novartis
C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J. Hassel, P. Rutkowski, C. McNeil, E. Kalinka‐Warzocha, K. Savage, M. Hernberg, C. Lebbé, J. Charles, C. Mihalcioiu, V. Chiarion-Sileni, C. Mauch, F. Cognetti, A. Arance, H. Schmidt, D. Schadendorf, H. Gogas, L. Lundgren-Eriksson, C. Horak, B. Sharkey, I. Waxman, V. Atkinson, P. Ascierto (2015)
Nivolumab in previously untreated melanoma without BRAF mutation.The New England journal of medicine, 372 4
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, M. Glabbeke, A. Oosterom, M. Christian, S. Gwyther (2000)
New guidelines to evaluate the response to treatment in solid tumorsBreast Cancer, 12
T. Landre, C. Taleb, P. Nicolas, G. Guetz (2016)
Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?Journal of Clinical Oncology, 34
H. Arkenau, J. Barriuso, D. Olmos, J. Ang, J. Bono, I. Judson, S. Kaye (2009)
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 16
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, M. Glabbeke, A. Oosterom, M. Christian, S. Gwyther (2000)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.Journal of the National Cancer Institute, 92 3
Yuka Kuriyama, Y. Kim, H. Nagai, H. Ozasa, Y. Sakamori, M. Mishima (2013)
Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung CancerCase Reports in Oncology, 6
S. Koyama, Esra Akbay, Yvonne Li, G. Herter-Sprie, Kevin Buczkowski, W. Richards, L. Gandhi, A. Redig, S. Rodig, H. Asahina, Robert Jones, Meghana Kulkarni, M. Kuraguchi, Sangeetha Palakurthi, P. Fecci, B. Johnson, P. Jänne, J. Engelman, Sidharta Gangadharan, D. Costa, G. Freeman, R. Bueno, F. Hodi, G. Dranoff, Kwok-kin Wong, P. Hammerman, P. Hammerman (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsNature Communications, 7
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, F. Finckenstein, J. Brahmer (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 17
James Anderson, K. Cain, R. Gelber (1983)
Analysis of survival by tumor response.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1 11
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 2
Fert e Acquisition of data (provided animals, acquired and managed patients, provided facilities
M. Hölzel, Anton Bovier, T. Tüting (2013)
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?Nature Reviews Cancer, 13
S. Kleffel, C. Posch, S. Barthel, Hansgeorg Mueller, C. Schlapbach, E. Guenova, C. Elco, N. Lee, Vikram Juneja, Q. Zhan, C. Lian, R. Thomi, W. Hoetzenecker, A. Cozzio, R. Dummer, M. Mihm, K. Flaherty, M. Frank, G. Murphy, A. Sharpe, T. Kupper, T. Schatton (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor GrowthCell, 162
Loise Francisco, P. Sage, A. Sharpe (2010)
The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 236
C. Ferté, S. Koscielny, L. Albiges, L. Rocher, J. Soria, R. Iacovelli, Y. Loriot, K. Fizazi, B. Escudier (2014)
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.European urology, 65 4
R. Solana, R. Tarazona, Inmaculada Gayoso, O. Lesur, G. Dupuis, T. Fulop (2012)
Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans.Seminars in immunology, 24 5
J. Chaft, G. Oxnard, C. Sima, M. Kris, V. Miller, Gregory Riely (2011)
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial DesignClinical Cancer Research, 17
Cancer Epidemiology, Biomarkers and Prevention – Unpaywall
Published: Nov 9, 2016
Access the full text.
Sign up today, get DeepDyve free for 14 days.